IMRT is the standard of care in the treatment of H&N carcinoma based on level 1 evidence. However, today there is a greater chance of missing the tumor due to uncertainties in target volume definition by the clinician that is demanded by the highly conformal planning process involved with IMRT. The aim of this work is to compare the outcome in 3D and IMRT treatments in our first two years using IMRT.
Results:
In this group of 152 patients, 30 (19%) recurrences were found: 21 (20%) in the group treated with 3D techniques (101 patients) and 9 (17%) in the group treated with IMRT (51 patients). 21 recurrences were in field, 2 of them in the elective nodal radiation field. Seven (23%) of the recurrences infield were included the IMRT group, and 21 (66%) in the 3D group. Tumor persistence was identified in 6 (20%) patients treated with 3D and 4 (13%) with IMRT. Recurrences outfield were similar in both techniques, lightly higher in the IMRT group (28% vs 33%). However, this data has no relevance keeping in mind he number of patients in each group. In the 3D group there were found 6 patients with early recurrence (before 6 months) and no patients in the IMRT group.
Conclusion:
In this group, recurrences were mostly infield, regardless of the employed technique. These data confirm conclusions previously published in large series with 3D radiotherapy. The IMRT group showed lower treatment failures and no early recurrences. However, it is needed to go on checking the IMRT implementation in the departments: to review possible uncertainties in target volume, to define the target with the best image techniques and to assess retrospectively the outcome. 
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Material and Methods:
We retrospectively reviewed patients with proved diagnosis of T4a (AJCC 7th) LSCC from 1983 to 2011 at MD Anderson Cancer Center under an approved IRB protocol. Primary tumors were manually contoured on pretreatment diagnostic CT scans for all patients with available scans then total tumor volumes were recorded. Cox regression multivariate analysis was done to investigate the impact of the following variables (age, sex, ethnicity, LSCC subsite of origin, performance status, nodal stage, surgical treatment, radiation use and dose, chemotherapy use, and tumor volume) on OS. Recursive partitioning analysis (RPA) was used to determine cut point of tumor volume associated with OS then Kaplan-Meier curves were plotted for groups above and below the RPA-derided cut point and log-rank tests was used to compare OS in both groups.
Results: A total of 124 patients were included. Median follow-up was 68 months, and median age at the time of diagnosis was 58 years. Table 1 summarizes patients, disease, and treatment characteristics.
A total of 83 patients (67%) received total laryngectomy followed by postoperative radiotherapy (TL-PORT), and 41 patients (33%) received larynx preservation (LP) with radiotherapy (RT). The distribution of sex was 101 males (81%) and 23 females (19%). On multivariate analysis, the only independent predictor of OS was tumor volume (HR 2.6; 95% CI 1.5-4.5, p=0.0006). RPA derived the cutpoint at 21cc. Patients with tumors ≥ 21cc had significantly worse 5-year OS compared to <21cc (44% vs. 64%, p=0.003) as in Figure 1 .
Conclusion:
Our results suggest that pretreatment primary tumor volume was the only independent predictor of OS in T4a LSCC patients. We recommend the routine measurement ________________________________________________________________________________ of primary tumor volume for its prognostic impact and for treatment stratification in future clinical trials. : From Feb. 2008 to Nov. 2009 , a total of 467 subjects coming to an otorhinolaryngology outpatient clinic were enrolled in a prospective screening study. Paired serum and plasma samples were collected and subjected to an immunofluorescence assay for IgA antibodies against the viral capsid antigen (VCA) and early antigen (EA) and a realtime quantitative polymerase chain reaction assay for pEBV DNA measurement. Nasopharyngoscopy was done for subjects with risk factors associated with NPC or abnormal reports of blood tests. Biopsy was performed for suspected lesions to confirm the diagnosis.
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Results:
We divided the studied population into three subgroups-group A (n= 139, symptoms/signs mimicking NPC, presence of family history of NPC, or abnormal antibody tests at other hospital), group B (n= 191, symptoms/signs not related to NPC), and group C (n= 137, healthy volunteers). After a minimal follow-up of five years, 9 of 467 screened subjects were proven to have NPC. All NPC patients were found in the group A. The sensitivity, specificity, positive predictive value, and negative predictive value for the pEBV DNA test were 100%, 99.8%, 90.0%, and 100%. The sensitivity, specificity, positive predictive value, and negative predictive value for the VCA-IgA test were 77.8%, 88.9%, 12.1%, and 99.5%. The corresponding numbers for the EA-IgA test were 33.3%, 97.6%, 21.4%, and 98.7%.
